معرفی
Jean-Baptiste Woillard is a Professor of Medical Pharmacology at the Faculty of Medicine in Limoges and serves as the head of the "Pharmacometrics and Artificial Intelligence" functional unit within the Department of Pharmacology, Toxicology, and Pharmacovigilance at the University Hospital of Limoges. He also functions as deputy director at Inserm U1248 "Pharmacology & Transplantation" and is actively involved with the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), where he previously served as president of the Pharmacometrics Committee. His professional affiliations include membership in the European Association for Clinical Pharmacology and Therapeutics (EACPT) and the French Society of Pharmacology and Therapeutics (SFPT).
Dr. Woillard obtained his PharmD from the University of Toulouse in 2004, followed by a Master's degree in Pharmacology in 2007, and completed his Ph.D. in Pharmacogenetics and Pharmacokinetics in 2011. His academic progression includes positions as Assistant Professor (2010-2014), Associate Professor (2014-2023), and Professor (since 2023) within the Pharmacology, Toxicology Department at the University Hospital of Limoges/INSERM U1248.
His research focuses on pharmacometrics modeling, artificial intelligence applications in personalized medicine, and pharmacogenetics. Dr. Woillard's work centers on the personalization of treatments, particularly concerning immunosuppressants in organ transplantation. His research encompasses pharmacogenetic and pharmacodynamic studies, development of pharmacokinetic models, statistical modeling, and the application of machine learning methods to therapeutic drug monitoring. Since 2019, his research has increasingly incorporated AI methodologies to optimize drug dosing and treatment outcomes.
Analysis of Dr. Woillard's recent publications reveals a strong emphasis on applying machine learning to pharmacokinetic modeling and therapeutic drug monitoring across various medications including immunosuppressants, antibiotics, and antivirals. His work demonstrates a consistent trajectory toward developing sophisticated algorithms for dose individualization, with particular focus on mycophenolate, tacrolimus, ganciclovir, and daptomycin. The research shows increasing integration of AI techniques with traditional pharmacometric approaches to create more precise dosing strategies.
- IFCC-Gérard Siest Young Scientist Award (2020) for Distinguished Contributions in Pharmacogenetics
- Recipient of 1.8 million euros funding through the French PEPR framework for developing multi-scale pharmacological digital twins
Dr. Woillard has published over 130 articles in peer-reviewed international scientific journals, delivered more than 30 presentations at national and international conferences, and has been invited to give over 40 academic and industry talks. He leads a significant research consortium focused on developing multi-scale pharmacological digital twins, demonstrating his leadership in securing substantial research funding. His work bridges clinical practice with advanced computational methodologies to improve patient outcomes through personalized medicine approaches.
As head of the "Pharmacometrics and Artificial Intelligence" functional unit at the Department of Pharmacology, Toxicology, and Pharmacovigilance (CHU of Limoges), Dr. Woillard directs research efforts focused on treatment personalization, particularly for immunosuppressants in organ transplantation. His team collaborates extensively within the Inserm U1248 unit "Pharmacology & Transplantation," working on both fundamental pharmacological research and clinical applications of their findings. The research group maintains active collaborations with international organizations including the IATDMCT and EACPT.
